CONMED Corporation has appointed Celine Martin and Jeff Mirviss to its Board of Directors, strengthening the company’s leadership and strategic expertise.
CONMED Corporation has announced the appointment of two seasoned healthcare industry leaders, Celine Martin and Jeff Mirviss, to its Board of Directors, further strengthening the company’s leadership as it continues to pursue long-term strategic growth in the global medical technology market. The appointments will officially become effective on July 1, 2026, and are expected to enhance the company’s governance capabilities with decades of combined experience in medical devices, commercial operations, strategic expansion, and healthcare innovation.
As part of the announcement, CONMED confirmed that the size of its Board will increase to nine directors. Both newly appointed board members will immediately assume committee responsibilities aligned with their professional expertise. Martin will serve on the Audit Committee as well as the Strategy Committee, while Mirviss will join the Compensation Committee and the Corporate Governance and Nominating Committee.
The addition of Martin and Mirviss represents a significant move for CONMED as the company continues to expand its footprint in the competitive MedTech industry. Both executives bring leadership experience from some of the world’s largest healthcare organizations, including Johnson & Johnson and Boston Scientific, where they oversaw large-scale global operations and contributed to major innovations in patient care technologies.
LaVerne Council, Chair of CONMED’s Board of Directors, welcomed the appointments and emphasized the strategic value both executives will bring to the organization. According to Council, Martin and Mirviss each possess deep operational and leadership expertise developed through decades of experience managing complex healthcare businesses at a global scale.
Council noted that Martin’s 30-year career at Johnson & Johnson provided her with extensive international leadership exposure across multiple areas of medical technology. Her experience includes advancing innovations in cardiovascular care, minimally invasive surgery, and other specialized therapeutic areas. Council also highlighted Martin’s strong record in driving business growth and developing new healthcare technology categories that have influenced standards of care across the industry.
Similarly, Council praised Mirviss for his long-standing leadership at Boston Scientific, where he managed complex global medical device businesses and demonstrated operational excellence across numerous therapeutic segments. His experience overseeing multinational commercial organizations and navigating evolving healthcare markets is expected to contribute significantly to CONMED’s long-term strategic direction.
Patrick Beyer, President and Chief Executive Officer of CONMED, also expressed enthusiasm regarding the appointments. Beyer stated that both Martin and Mirviss will add important perspectives to the Board at a time when the company is focused on sustaining innovation, enhancing governance, and delivering value to stakeholders.
According to Beyer, Martin’s expertise in scaling high-growth medical technology businesses and her global strategic leadership experience complement Mirviss’s strengths in operational execution and portfolio management. Together, their backgrounds are expected to support CONMED’s ongoing efforts to improve outcomes for patients while strengthening relationships with healthcare providers, customers, and shareholders worldwide.
Martin joins CONMED after an accomplished three-decade career at Johnson & Johnson, where she held several senior leadership positions in both the United States and international markets. Throughout her tenure, she played a major role in advancing the company’s MedTech ambitions and supporting the development of innovative treatment solutions in areas including atrial fibrillation, stroke management, and minimally invasive surgical technologies.
Most recently, Martin served as Company Group Chairman leading Johnson & Johnson MedTech’s Cardiovascular & Specialty Solutions Group from 2022 through 2025. In that role, she oversaw a diverse collection of rapidly growing businesses focused on electrophysiology, neurovascular intervention, ear, nose and throat therapies, and breast aesthetics. Her leadership responsibilities included guiding strategy, accelerating innovation, and expanding the company’s presence across multiple healthcare segments.
Prior to leading the Cardiovascular & Specialty Solutions Group, Martin headed the Ethicon Endo Surgery business, where she helped establish foundational capabilities in robotic and digital surgery technologies. Her work contributed to the growing adoption of minimally invasive and digitally enabled surgical solutions, areas that continue to transform modern operating rooms and surgical practices globally.
Martin’s educational background includes an MBA from Wake Forest University as well as a graduate degree in marketing from Normandy Business School. In addition to joining CONMED’s Board, she also serves on the Board of Directors of H.B. Fuller, further reflecting her broad executive and governance experience.
Mirviss also brings extensive healthcare industry expertise to CONMED’s Board, with more than 35 years of leadership experience spanning commercial strategy, global operations, and medical device innovation. Most recently, he served as Executive Vice President and Global President of Peripheral Interventions at Boston Scientific from 2020 to 2025.
In that position, Mirviss oversaw a multi-billion-dollar global business focused on therapies for vascular disease and cancer treatment. His leadership portfolio extended beyond product operations to include responsibility for Boston Scientific’s Latin America and Canada regions, as well as oversight of the company’s Government Affairs function.
Before becoming Executive Vice President, Mirviss served as Senior Vice President and Global President of Peripheral Interventions between 2013 and 2020. Earlier in his career, he held the role of Global President of Peripheral Interventions from 2011 to 2013 and advanced through multiple senior management positions at Boston Scientific. These included leadership roles overseeing global marketing activities across the company’s cardiology, rhythm management, and vascular businesses.
Mirviss earned a Bachelor of Individualized Studies degree in Marketing from the University of Minnesota and later completed an MBA at the University of St. Thomas.
The appointments come at a time when CONMED continues to focus on innovation, operational growth, and strengthening its position within the global surgical and medical technology markets. By adding executives with deep experience in cardiovascular technologies, minimally invasive surgery, interventional therapies, and global healthcare operations, the company is reinforcing its commitment to long-term strategic execution and governance excellence.
Industry observers may view these additions as a reflection of CONMED’s broader ambitions to accelerate growth and compete more aggressively across evolving medical technology sectors. With healthcare systems increasingly prioritizing innovation, digital integration, and improved patient outcomes, the experience Martin and Mirviss bring from two of the industry’s largest MedTech organizations could provide valuable guidance as CONMED navigates future opportunities and challenges.
Their appointments also underscore the growing importance of experienced leadership within healthcare companies facing rapid technological advancements, regulatory complexity, and increasing global competition. As CONMED expands its Board and deepens its expertise, the company appears positioned to continue building on its strategic initiatives while pursuing innovation-driven growth in the years ahead.
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery.
